News - Page 102 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

Post published:July 7, 2022
Post category:Press Release

Read more about the article PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Post published:July 5, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis of NEJM Psilocybin vs. Escitalopram Trial; Off-Label = Off the Rails?

Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis of NEJM Psilocybin vs. Escitalopram Trial; Off-Label = Off the Rails?

Post published:July 4, 2022
Post category:Psychedelic Bulletin

Read more about the article FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT OF UNITS AND CONVERTIBLE DEBENTURE UNITS OF UP TO $2,500,000

FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT OF UNITS AND CONVERTIBLE DEBENTURE UNITS OF UP TO $2,500,000

Post published:July 1, 2022
Post category:Press Release

Read more about the article atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

Post published:July 1, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

Post published:June 29, 2022
Post category:Press Release

Read more about the article Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

Post published:June 29, 2022
Post category:Press Release

Read more about the article Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation

Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation

Post published:June 29, 2022
Post category:Press Release

Read more about the article Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA

Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA

Post published:June 29, 2022
Post category:Press Release

Read more about the article HAVN Life Enters Supply Agreement with MPB Group Inc.

HAVN Life Enters Supply Agreement with MPB Group Inc.

Post published:June 29, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.